![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Efficacy of the Combination HCV Regimen Elbasvir and Grazoprevir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naive,
Non-Cirrhotic HCV GT1b-Infected Patients: An Integrated Analysis
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Serfaty L1; Zeuzem S2; Vierling JM3; Howe A4*; Hwang P4;
Robertson M4; Butterton J4; Wahl J4; Barr E4; Haber B4
1Université Pierre & Marie Curie, Paris, France;
2Goethe University Hospital, Frankfurt, Germany; 3Baylor
St. Luke's Medical Center, Houston, TX, USA; 4Merck & Co.,
Inc., Kenilworth, NJ, USA. *Former employee of Merck & Co., Inc.
In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile........ http://www.natap.org/2012/EASL/EASL_46.htm
Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4A Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in genotype-1 and -3 HCV-Infected Patients..... http://www.natap.org/2011/hepDART/hepDART_10.htm
MK-5172, the 1st HCV Protease Inibitor with Potent Acyivity Against Resistance Mutations In Vitro........ http://www.natap.org/2010/EASL/EASL_38.htm
AASLD: Resistance Analysis [and activity] of Genotype-1 and -3 HCV-Infected Patients Receiving MK-8742, an HCV NS5A Inhibitor With Potent Antiviral Activity, in a Ph1b Monotherapy Study - (11/05/13)
MK-8742, an HCV NS5A Inhibitor With a Broad Spectrum of HCV
Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and -3 HCV-Infected Patients...... http://www.natap.org/2013/AASLD/AASLD_20.htm
![AASLD1.gif](../images/010416/010416-5/AASLD1.gif)
![AASLD2.gif](../images/010416/010416-5/AASLD2.gif)
![AASLD3.gif](../images/010416/010416-5/AASLD3.gif)
![AASLD4.gif](../images/010416/010416-5/AASLD4.gif)
![AASLD5.gif](../images/010416/010416-5/AASLD5.gif)
![AASLD6.gif](../images/010416/010416-5/AASLD6.gif)
![AASLD7.gif](../images/010416/010416-5/AASLD7.gif)
![AASLD8.gif](../images/010416/010416-5/AASLD8.gif)
![AASLD9.gif](../images/010416/010416-5/AASLD9.gif)
![AASLD10.gif](../images/010416/010416-5/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|